Ariel Investments Dumps POZEN Inc. (POZN) Shares; Trigran Investments Boosts Stake In NVE Corp (NVEC)

John W. Rogers has almost halved his fund’s stake in POZEN Inc. (NASDAQ:POZN), as reported in a recent filing with the Securities and Exchange Commission. Rogers’ fund, Ariel Investments, has reported a 41% decrease in its holding of the stock to approximately 1.81 million shares, which account for 5.9% of the total number of shares outstanding.

POZEN Inc. (NASDAQ:POZN)

POZEN Inc. (NASDAQ:POZN) is also in the portfolio of Par Capital Management, which is managed by Paul Reeder and Edward Shapiro. They have made no change to the fund’s position during the first quarter of 2014, so Par Capital still holds 3.35 million shares. Jim Simons has decreased his fund’s stake by 5% during the same period, leaving Renaissance Technologies with approximately 238,100 shares. John Overdeck and David Siegel, on the other hand, have added to their stake in POZEN Inc. (NASDAQ:POZN), taking it to 123,200 shares, as reported by Two Sigma Advisors in its latest 13F filing.

According to another report, Douglas T. Granat and his fund, Trigran Investments, have increased their position in NVE Corp (NASDAQ:NVEC). In a filing with the SEC, Trigran Investment has revealed the addition of 11,490 shares, taking its stake to approximately 459,800 shares. The fund’s current stake amasses 9.5% of the company’s common stock.

Gregory Bylinsky And Jefferson Gramm, the managers of Bandera Partners, are also keeping an eye on NVE Corp (NASDAQ:NVEC), as their fund holds 63,606 shares according to its latest 13F filing. Jim Simons and David E Shaw have decreased their fund’s holding of this stock during the first quarter of this year. As a result, Simons’ Renaissance Technologies holds 8,500 shares, down 57% from the end of 2013, while D E Shaw has reported ownership of 6,538 shares at the end of the first quarter, following a 17% decrease in the position.

Disclosure: none.

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!